1 research outputs found
Discovery and Longitudinal Evaluation of Candidate Protein Biomarkers for Disease Recurrence in Prostate Cancer
When
compared with hormonal therapy alone, treatment with combined
hormone and radiation therapy (CHRT) gives improved disease-specific
survival outcomes for patients with prostate cancer; however, a significant
number of CHRT patients still succumb to recurrent disease. The purpose
of this study was to use longitudinal patient samples obtained as
part of an ongoing noninterventional clinical trial (ICORG06-15) to
identify and evaluate a potential serum protein signature of disease
recurrence. Label-free LC–MS/MS based protein discovery was
undertaken on depleted serum samples from CHRT patients who showed
evidence of disease recurrence (<i>n</i> = 3) and time-matched
patient controls (<i>n</i> = 3). A total of 104 proteins
showed a significant change between these two groups. Multiple reaction
monitoring (MRM) assays were designed for a subset of these proteins
as part of a panel of putative prostate cancer biomarkers (41 proteins)
for evaluation in longitudinal serum samples. These data revealed
significant interpatient variability in individual protein expression
between time of diagnosis, disease recurrence, and beyond and serve
to highlight the importance of longitudinal patient samples for evaluating
the use of candidate protein biomarkers in disease monitoring